Clinical Trial Update: Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors [Phase 1]

View source ↗

Summary

Completed Phase 1 trial evaluating tanespimycin in pediatric patients with recurrent or refractory leukemia or solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia
• Desmoplastic Small Round Cell Tumor
• Ewing Sarcoma
• Neuroblastoma
• Osteosarcoma
• Rhabdomyosarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• tanespimycin (17-N-allylamino-17-demethoxygeldanamycin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Childhood Chronic Myelogenous Leukemia, Childhood Desmoplastic Small Round Cell Tumor | Phase 1 | Status: COMPLETED